NEJM: Single-Dose In-Vivo B-Cell Depletion Helps All 16 Refractory Autoimmune Patients
EricTopol · x · 2026-09-03
Eric Topol highlights a NEJM study on in-vivo B-cell depletion for refractory autoimmune neurologic conditions: all 16 patients — including 7 with progressive multiple sclerosis — showed clinical and biologic improvement after a single dose using an off-the-shelf lentiviral vector. The approach bypasses the complicated, laborious ex-vivo methods used until now, advancing B-cell depletion from a complex procedure toward a potentially curative, scalable option for autoimmune disease.
More from Research
- Counterfactual Debugging: causal attribution over 1M steps to localize sim2real gaps in world-model agents — MichaelD1729 · 2026-09-03
- DeepMind's 83-Page Study: Autonomous Research Agents Fabricate 90% of Findings — williamtp · 2026-09-03
- How Google's RT-2 triggered the robotics boom: Understanding AI explains VLA models — binarybits · 2026-09-03
- Goodfire chief scientist Tom McGrath on interpretability: SAEs may fracture what networks really learn — Machine Learning Street Talk · 2026-09-03
- CBAI opens Fall AI Safety fellowship: $15k stipend, 10 weeks in Boston — benno_krojer · 2026-09-03
- What 12 million empirical research results can teach us — RexDouglass · 2026-09-03